Description: Antisense Therapeutics Limited (ANP) is an Australia-based pharmaceutical drug discovery and development company. The Company is engaged in the research and development of antisense pharmaceuticals. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly, diabetic retinopathy and diabetic nephropathy. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company's product candidate, ATL1101, is an antisense inhibitor of insulin like growth factor 1 receptor (IGF-Ir). It is developing ATL1101 for the treatment of prostate cancer. It is also developing ATL1102 as an inhaled treatment for asthma.
Home Page: www.antisense.com.au
ANP Technical Analysis
14 Wallace Avenue
Toorak,
VIC
3142
Australia
Phone:
61 3 9827 8999
Officers
| Name | Title |
|---|---|
| Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD | CEO, MD & Director |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | CFO & Joint Company Sec. |
| Dr. George Tachas | Director of Drug Discovery & Patents |
| Ms. Nuket Desem | Director of Clinical and Regulatory affairs |
| Dr. Anthony Filippis | Chief Commercial Officer |
| Ms. Alicia Mellors | Joint Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8481 |
| Price-to-Sales TTM: | 33.1153 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |